- Home
- HNNA vs ADAP Comparison
HNNA vs ADAP Comparison
Compare HNNA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNNA
- ADAP
- Stock Information
- Founded
- HNNA 1989
- ADAP 2008
- Country
- HNNA United States
- ADAP United Kingdom
- Employees
- HNNA N/A
- ADAP N/A
- Industry
- HNNA Investment Managers
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- HNNA Finance
- ADAP Health Care
- Exchange
- HNNA Nasdaq
- ADAP Nasdaq
- Market Cap
- HNNA 86.4M
- ADAP 75.5M
- IPO Year
- HNNA N/A
- ADAP 2015
- Fundamental
- Price
- HNNA $12.35
- ADAP $0.25
- Analyst Decision
- HNNA
- ADAP Buy
- Analyst Count
- HNNA 0
- ADAP 6
- Target Price
- HNNA N/A
- ADAP $1.35
- AVG Volume (30 Days)
- HNNA 7.8K
- ADAP 681.6K
- Earning Date
- HNNA 08-07-2025
- ADAP 08-11-2025
- Dividend Yield
- HNNA 4.45%
- ADAP N/A
- EPS Growth
- HNNA 83.55
- ADAP N/A
- EPS
- HNNA 1.25
- ADAP N/A
- Revenue
- HNNA $35,546,000.00
- ADAP $179,639,000.00
- Revenue This Year
- HNNA N/A
- ADAP N/A
- Revenue Next Year
- HNNA N/A
- ADAP $35.48
- P/E Ratio
- HNNA $9.88
- ADAP N/A
- Revenue Growth
- HNNA 41.94
- ADAP 878.53
- 52 Week Low
- HNNA $7.10
- ADAP $0.20
- 52 Week High
- HNNA $13.88
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- HNNA 77.45
- ADAP 45.94
- Support Level
- HNNA $10.86
- ADAP $0.23
- Resistance Level
- HNNA $12.73
- ADAP $0.25
- Average True Range (ATR)
- HNNA 0.48
- ADAP 0.02
- MACD
- HNNA 0.11
- ADAP -0.00
- Stochastic Oscillator
- HNNA 97.64
- ADAP 54.55
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.